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Effect of Platinum and Palladium
Salts on Thymidine Incorporation
into DNA of Rat Tissues
byRichard F. Fisher,* David J. Holbrook, Jr.,* Hansford B.
Leake,* and Paul E. Brubakert
The intraperitoneal administration of PtCl4 or Pd(NO3)2 at levels of 28 or 56 ,umole/kg
body weight decreased the thymidine incorporation into DNA ofspleen, liver, kidney, and
testis. Spleen was most sensitive to both the platinum and the palladium salt. In liver, DNA
syntheses in parenchymal cells and stromal cells were about equally sensitive to PtCl4. In
control rats, only 20-30% ofthe 3H in the acid-soluble fraction ofliver or spleen was in the
form of thymidine and its phosphate esters 2 hr after the intraperitoneal injection of 3H-
thymidine; prior injection of PtCl4 (56 ,umole/kg body weight) did not change the pattern.
Introduction
Platinum and palladium compounds currently
are being used as the active components in the
catalytic converters of air pollution control devices
on many motor vehicles. It is of interest, therefore,
to determine the biological effects of the com-
pounds of these metals. The present experiments
were conducted to determine the acute effects of
soluble salts of platinum and palladium on the in-
corporation of radioactive thymidine into DNA.
Materials and Methods
All experimental studies were conducted with
male Sprague-Dawley rats (weighing 160-200 g)
obtained from Zivic-Miller Laboratories. In each of
these experiments, the metallic salt and the 3H-
labeled thymidine were injected intraperitoneally
4 hr and 2 hr, respectively, before the removal of
the tissues. The 3H-thymidine was injected at a
level of 99 ,uCi/kg body weight, except that a level
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of 990 ,uCi/kg body weight was used when the dis-
tribution of 3H in the acid-soluble fraction was
under study (i.e., Table 5). (3H-methyl) thymidine
was purchased from New England Nuclear,
Pd(NO3)2 aqueous solution from Research
Organic/Inorganic Chemical, and PtCl4 from the
latter firm and from B.F. Goldsmith Chemical and
Metal.
The administered doses of PtCl4 and Pd(NO3)2
were 14, 28, and 56 ,tmole/kg body weight. For
PtCl4, these doses corresponded to 2.8, 5.5, and 11
mg Pt4+/kg. For Pd(NO3)2, the doses by weight were
equal to 1.5, 3, and 6 mg Pd2+/kg body weight. The
highest dose of Pt, namely 56 ,mole/kg, was equal
to one-half of the intraperitoneal LD50. However,
because of the steep slope of the lethal dose curve,
the dose of 56 ,umole PtCl4/kg was appreciably less
than the LD5.
Thymidine incorporation was measured in
spleen, liver, kidney, and testis. Tissue
macromolecules were precipitated with cold 0.5M
HCl04 and, after centrifugation, the supernatant
was collected as the acid-soluble fraction. The
RNA in the pellet was hydrolyzed with 0.3M NaOH
(37°C, 1 hr) and the intact macromolecules were
precipitated with cold HCl04 (final concentration
ofHCl04 not neutralized, 0.5M). The DNA was hy-
drolyzed in hot HCl04 (0.5M, 90°C, 20 min). After
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was collected. The acid-soluble fraction and the hy-
drolyzed DNA were analyzed for nucleotide con-
centration by measuring the absorbance at 260 nm.
Tritium was measured by scintillation counting by
using a mixture containing toluene and Triton
X-100 (1).
The radioactivity in the DNA is expressed as
counts per minute (cpm)/,mole DNA-nucleotide.
The radioactivity in the acid-soluble fraction is ex-
pressed as cpm/,umole total acid-soluble nucleo-
tide. The radioactivity is also expressed as a ratio
of the two values, i.e., as cpm/Aumole DNA-
nucleotide divided bycpm/,umoletotal acid-soluble
nucleotide. This ratio takes into consideration two
factors: (a) the total amount of radioactivity
available for incorporation into tissue DNA, and
(b) any variation in isotope concentration in the
same tissue ofdifferent rats within an experimental
group.
N-1 nuclei from hepatic parenchymal cells and
N-2 nuclei from hepatic stromal cells were isolated
according to the method of Potter and co-workers
(2, 3). The method is similar in principle to the
method used previously in this laboratory for the
fractionation ofnuclei from control and regenerat-
ing liver (4).
The absorption of nucleotides and related com-
pounds by charcoal from acidic solution was con-
ducted according to the method of Tsuboi and
Price (5). The charcoal-absorbed compounds were
eluted from the charcoal by two treatments with
1% ammonia in 60% ethanol (5). The eluted char-
coal-absorbable compounds were chromato-
graphed on thin layer sheets of polyethylene-
imine-cellulose with 0.02M ammonium
acetate-95% ethanol (1:1, v/v). Thymidine and
thymine migrated to the solvent front; thymidine
phosphates remained at or near the origin.
Results
The effects of PtCl4 on thymidine incorporation
into DNA ofrat tissues are presented in Table 1. In
the tissues studied, the incorporation of thymidine
into spleen, DNA was the most sensitive to
platinum. In spleen, thymidine incorporation was
reduced by one-third at the lowest dose of PtCl4.
The two higher doses of PtCl4 decreased thymidine
incorporation by 50% or more. The ratios
(DNA/acid-soluble fraction) gave the same pattern
of inhibition. The incorporation of thymidine into
liver DNA was not as sensitive to platinum as was
the incorporation into spleen DNA. Although no in-
hibition was observed in liver at a dose of 14
,umole/kg, thymidine incorporation was inhibited
by 40% and the ratio approached that observed in
spleen at a dose of 56 ,mole/kg. At the latter dose,
the radioactivity in the acid-soluble fraction (ASF)
was increased by approximately 50%. In kidney,
thymidine incorporation into DNA was inhibited
40-50% at doses of 28 or 56 ,umole/kg. At the two
highest doses, the ratios in kidney approached
those obtained in spleen. As in the case ofliver, the
radioactivity in the acid-soluble fraction was in-
creased by approximately 50% at the highest dose
ofPtCl4. In testis, the thymidine incorporation into
Table 1. Effect ofPtCl4 on incorporation ofthymidine into DNA ofrat tissues.a
No. of PtCl4, DNA Acid-soluble fraction (ASF) DNA/ASF
Tissue samples ,umole/kg cpm/,umole % of control cpm/,umole % of control Ratio % of control
Spleen 6 0 1560 ± 160 4950 ± 140 - 0.319 ± 0.039
4 14 67± 6" 105± 4 63± 7"
4 28 48± 2+ 110± 4t 43± 2t3
6 56 42 ± 3+ 105 ± 5 40 ± 5t
Liver 14 0 824 + 106 2050 ± 180 0.428 ± 0.064
4 14 100 24 118 ± 19 100± 47
10 28 87 15 113 ± 10 78± 14
8 56 60 11* 147 ± 17* 45 ± 14*
Kidney 8 0 382 ± 58 5110 ± 170 - 0.075 ± 0.011
4 14 99 19 99 ± 10 107 ± 31
4 28 58 ± 5* 118 ± 8t 50 ± 7*
8 56 50± 4t 151 ± 15t 35 ± 4t
Testis 8 0 402 ± 74 6880 ± 320 0.057 ± 0.009
4 14 127 ± 8 113 ± 4t 116± 11
4 28 75 10 114 ± 3* 67 ± 9
8 56 74 9 118 ± 3t 64 ± 7t
aAll values ± S. E. Statistical analysis (t-test): dagger (t) denotesp < 0.01; asterisk (*),p < 0.05; double dagger (t), 0.05 < p <
0.10. PtCl4 and 3H-thymidine were injected intraperitoneally at 4 hr and 2 hr, respectively, before removal of the tissues.
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No. of PtCD4, DNA Acid-soluble fraction (ASF) DNA/ASF
Tissue samples ,umole/kg cpm/,Lmole % of control cpm/Amole % of control Ratio % of control
Spleen 6 0 1550 ± 200 5030 ± 300 0.316 ± 0.052
4 14 78+ 12 119± 6t 65± 11
6 28 52 12* 111 7 49± 13*
7 56 44± lit 107± 4 41 ± 11*
Liver 6 0 700 ± 129 2230 ± 520 0.342 ± 0.047
4 14 73 16 115 27 60± 6*
6 28 70 19 138 22 55 21t
7 56 59 15 105 19 55 10*
Kidney 6 0 263 ± 57 5590 ± 100 0.048 ± 0.011
4 14 88 14 108± 7 84 20
6 28 93 31 104 3 88± 29
7 56 59 14 105 6 56± 13
Testis 6 0 380 ± 53 6310 ± 250 0.062 ± 0.012
4 14 107 7 105 10 102± 14
6 28 59 17t 108 5 56± 18
7 56 40 9t 118 4* 33± 7t
'All values ± S.E. Statistical analysis (t-test): dagger (t) denotesp < 0.01; asterisk (*), p < 0.05; double dagger (t), 0.05 <p <
0.10. PtCl4 and :3H-thymidine injected intraperitoneally at 4 hr and 2 hr, respectively, before removal of the tissues.
DNA and the ratio were decreased by 25-35% by
doses of PtCl4 of 28 or 56 ,Amole/kg.
Thymidine incorporation into DNA of spleen
was very sensitive to the administration of
Pd(NO3)2, just as it was to PtCl4 (Table 2). Moder-
ate decreases were found in thymidine incorpora-
tion into DNA and in the ratio of spleen at the
lowest dose of Pd(NO3)2. At the two highest doses,
50-60% inhibition was observed in the DNA and
the ratio. Pd(NO3)2 decreased incorporation into
DNA and the ratio of liver by 25-45%, depending
on the dosage. The kidney was relatively resistant
to treatment with Pd(NO3)2. The maximum inhibi-
tion in incorporation in kidney was approximately
40% with a corresponding decrease observed in the
ratio. Thymidine incorporation into DNA of testis
was markedly inhibited at the two higher doses of
Pd(NO3)2 and the inhibition ranged from 40% to
60%; the decrease in the ratio was comparable at
each dose.
The administration of Pt or Pd did not cause a
decrease in radioactivity in the acid-soluble frac-
tion in any of the tissues studied (Tables 1 and 2).
Thus, the administration of either PtCl4 or
Pd(NO3)2 did not decrease the circulation of the
radioactive thymidine from its site of injection
and/or the entrance of the thymidine into the
tissue. Increases in acid-soluble radioactivity were
noted in some experiments. The highest dose of Pt
caused this effect in liver, kidney and testis but not
in spleen. In contrast, the highest dose ofPd caused
an increase only in testis.
Potter et al. (2, 3) developed a method for the
fractionation ofliver nuclei into two classes: nuclei
derived from parenchymal cells or hepatocytes
(called N-1 nuclei) and nuclei derived from stromal
Table 3. Effect ofPtCI4 on incorporation ofthymidine into nuclei ofparenchymal (N-1) and stromal (N-2) cells ofliver.a
Experiment A Experiment B
No PtCl4 PtCl4 = 28 /Amole/kg No PtCl4 PtCl4 = 56 ,umole/kg
DNA, cpm/,umole
Total cellular 810 ±220 910 ± 260 (112%)b 660 ± 230 410 ± 70 (62%)"
N-1 nuclei 1590± 380 1670± 190 (105%) 730± 240 400 ± 160 (55%)
N-2nuclei 700± 140 710± 130 (101%) 450± 60 300 ± 40t (65%)
Ratio: DNA/acid-soluble fraction
Total cellular 0.51 ± 0.15 0.45 ± 0.12 (89%) 0.28 ± 0.04 0.11 ± 0.01* (41%)
N-1 nuclei 0.99 ± 0.28 0.83 ± 0.14 (84%) 0.31 ± 0.05 0.11 ± 0.02t (36%)
N-2 nuclei 0.43 ± 0.09 0.34 ± 0.06 (79%) 0.21 ± 0.04 0.09 ± 0.02* (41%)
DNA ratio
N-2 nuclei/N-1 nuclei ofsame sample 0.51 ± 0.15 0.42 ± 0.05 0.71 ± 0.10 0.82 ± 0.18
aNumber ofsamples was 4 at each level ofPtCl4 for both Experiments A and B. All values ± S.E. Statistical analysis (t-test): dag-
ger (t) denotes p < 0.01; asterisk (*), p < 0.05; double dagger (t), 0.05 < p < 0.10. PtCl4 and :3H-thymidine were injected in-
traperitoneally at 4 hr and 2 hr, respectively, before removal of tissues.
'Values in parentheses are % ofthe control values in the same experiment.
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Dose of Dose of DNA ASF DNAIASF
CC14, PtCl4, No. of % of % of % of
Tissue Group ml/kg iLmole/kg samples cpm/.umole group B cpm/,umole group B Ratio group B
Spleen A 0 0 3 1800 ± 200 91 3790 1120 102 0.57 ± 0.16 82
B 1.0 14 3 1990 ± 530 - 3720 850 0.70 ± 0.37
C 1.0 28 4 1410 ± 210 71 4420 ± 490 119 0.35 ± 0.11 50
Liver A 0 0 4 580 ± 130 10 1850 90 58 0.32 ± 0.09 16
B 1.0 14 5 6070 ± 1540 - 3180 690 - 2.00 ± 0.50
C 1.0 28 4 7610 ± 1940 125 2710 + 1030 85 3.15 ± 0.46 157
Kidney A 0 0 4 300 ± 60 100 6240 ± 1150 108 0.052 ± 0.012 100
B 1.0 14 5 300 ± 50 5790 290 0.052 ± 0.009
C 1.0 28 4 200 ± 40 67 7090 1530 122 0.032 ± 0.009 61
Testis A 0 0 4 540 ± 80 114 7450 ± 120 106 0.073 ± 0.012 108
B 1.0 14 5 470 ± 50 7050 290 - 0.067 ± 0.005
C 1.0 28 4 310 ± 40* 65 6860 360 97 0.039 ±0.Ollt 58
'All values ± S.E. Statistical analysis (t-test): asterisk (*) denotesp < 0.05; dagger (t), 0.05 < p < 0.10. CC14, diluted in corn oil,
was injected intraperitoneally at 42 hr, PtCI4 at 4 hr, and 3H-thymidine at 2 hr before removal of the tissues.
cells or non-hepatocytes (called N-2 nuclei). The
effects of PtCl4 on the incorporation of thymidine
into DNA of N-1 and N-2 nuclei are presented in
Table 3. In experiment A, no inhibition in
thymidine incorporation occurred in either class of
nuclei, and only a small decrease in the ratio was
observed at a dose of PtCl4 of 28 Amole/kg.
However, in experiment B, a PtCl4 dose of 56
,umole/kg decreased thymidine incorporation into
DNA to 60% of control values. This dose of PtCl4
also decreased the ratios to approximately 40% of
control values. Thus, in experiment B, thymidine
incorporation into both N-1 and N-2 nuclei was
depressed equally when expressed either as DNA
specific activities or as the ratios. Therefore,
thymidine incorporation was inhibited to an equal
extent in both parenchymal cells and stromal cells.
In control rats, the specific activities ofDNA are
in the following decreasing order: DNA of N-1
nuclei > total cellular DNA > DNA ofN-2 nuclei;
the specific activities of DNA from N-2 nuclei are
approximately two-thirds those of DNA of N-1
nuclei. In Table 3 the specific activities of DNA
from N-2 nuclei are expressed as a fraction of the
specific activities of DNA from N-1 nuclei in the
same experiment. Although the higher dose of
PtCl4 (Table 3) markedly inhibits thymidine incor-
poration in both cell types, the ratio of the N-2 to
N-1 specific activities is not significantly altered by
treatment with PtCl4.
The administratioh of CC14 to rats results in the
death of some hepatic cells and a rapid DNA syn-
thesis and mitotic activity in surviving cells in
order to replace the lost tissue. In data not shown,
it was found that thymidine incorporation into
DNA is approximately 8 to 10-fold greater in liver
ofthe CCl4-treated rats than in the control rats. In-
corporation has been studied in four tissues ofrats
which received CC14 and PtCl4 (Table 4). The data
for each tissue are compared to the values of
animals in group B, which received CC14 and a low
dose of PtCl4.
In liver, thymidine incorporation into DNA of
group B rats was 10-fold greater than that of rats
receiving no CC14. Moreover, increasing the dose of
PtCl4 to 28 ,mole/kg did not inhibit thymidine in-
corporation into liver DNA of CCl4-treated rats.
For spleen, kidney, and testis, thymidine incorpora-
tion into DNA ofeach tissue ofgroups A and B was
essentially equal. In these three tissues, in contrast
to the pattern seen in liver, thymidine incorpora-
tion in rats of group C (CC14 and 28 ,umole
PtCl4/kg) was decreased approximately 30% in
comparison with group B animals. The same pat-
tern of results was obtained for all three tissues if
the ratios ofDNA to acid-soluble fraction were ex-
amined. The ratio in liver of group C animals was
apparently (but not statistically) greater than in
liver of group B rats; in contrast, the ratios in
spleen, kidney, and testis were approximately 40%
less in group C animals. Thus, PtCl4 (at 28
Amole/kg) apparently did not inhibit the stimul-
ated synthesis of DNA of liver in CCl4-treated rats
but did inhibit thymidine incorporation into DNA
of the other three tissues, similar to the pattern
seen above (Table 1).
In these experiments, the radioactivity in the
acid-soluble fraction has been used as a reference
for the total availability ofradioactive precursor in
individual tissue samples. It was of interest,
therefore, to examine the distribution of radioac-
tivity in the acid-soluble fraction. The acid-soluble
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trol animals and in rats treated with 56 ,umole
PtCl4/kg, the highest dose used in the prior incor-
poration studies.
Charcoal adsorption was used to separate intact
pyrimidine compounds from their open-ring
metabolites. Only those compounds which had the
pyrimidine ring intact were adsorbed by charcoal
from an acidic solution. At the end of the 2-hr in-
corporation interval, the majority of the radioac-
tivity in the acid-soluble fraction was in the form of
the open-chain metabolites and other nonadsorbed
metabolites in. liverand spleen..of -control rats
(Table 5). In liver, 30% of the radioactivity in the
acid-soluble fraction was in the form ofcompounds
Table 5. Distribution of 3H-labeled compounds in the
acid-soluble fraction.a
Liver Spleen
No PtCl4 = 56 No PtCl4 = 56
PtCl4 umole/kg PtCl4 Atmole/kg
Charcoal adsorp-
tion, % of 3H in
acid-soluble fraction
Intact pyrimidine 30 28 22 23
compounds (28, 31) (22, 34) (20, 24) (19, 26)
(adsorbed)
Pyrimidine catabo- 70 72 78 77
lites (not (69,72) (66, 78) (76, 80) (74, 81)
adsorbed)
Thin layer chroma-
tography, % of 3H of
charcoal-adsorbable
fraction
Thymidine phos- 48 44 54 59
phates (47, 48) (37, 51) (54, 55) (54, 64)
Thymidine and 43 47 41 36
thymine mixture (43,44) (42,52) (41, 42) (33,40)
aMeans of values of two rats; percentage values of each rat
are given in parentheses. PtCl4 and 3H-labeled thymidine were
injected intraperitoneally 4 hr and 2 hr, respectively, before
removal of the tissues.
having the pyrimidine ring intact. Furthermore, the
administration of the highest dose of PtCl4 used in
these experiments did not alter this distribution. In
spleen the situation was similar. Approximately
22% of the radioactivity in the acid-soluble
fraction ofspleen ofcontrol rats was in the form of
intact pyrimidine compounds, and the administra-
tion of PtCl4 did not alter this value.
The charcoal-adsorbable compounds were
separated by thin-layer chromatography on
polyethyleneimine-cellulose. Two classes of com-
pounds were separated: (a) the thymidine phos-
phates, and (b) a mixture of thymidine and
thymine. In liver and spleen of control animals,
one-half of the total charcoal-adsorbable radioac-
tivity was in the form ofthymidine phosphates (Ta-
ble 5). Administration of PtCl4 did not appreciably
alter the values in these two tissues.
Discussion
The present study indicates that PtCl4 and
Pd(NO3)2 inhibitthe synthesis ofDNA as measured
by the incorporation of radioactive thymidine.
Waters et al. (6) report that the incorporation of
thymidine into DNA is more sensitive to inhibition
by PtCl4 than the incorporation of uridine into
RNA or of leucine into protein in cultured cells.
The inhibition by PtCl4 may be analogous to the
effect of Pt-containing antitumor compounds
(7-9). The inhibition of thymidine incorporation
into DNA is consistent with an inhibition of DNA
polymerase due to the interaction of the metallic
cations with the template DNA. The interaction in
vitro of the Pt-containing antitumor compounds
and ofPd2+ ions with DNA has been demonstrated
(10-12).
The structural features of the active antitumor,
Pt-containing compounds have a major role in the
activities of these compounds (8). It is unresolved
what modifications in biological effects are made
bythe selection ofthe salt PtCl4 for these studies. It
is unknown whether the rates of ionization or hy-
dration, and resultant biological effects, may be
significantly different if an alternate soluble Pt4+
salt such as Pt(SO4)2 had been selected for these
studies.
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